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Background: CD164 (endolyn), a sialomucin, has been reported to play a role in the proliferation, adhesion, and
differentiation of hematopoietic stem cells. The potential association of CD164 with tumorigenicity remains unclear.
Methods: The clinicopathological correlation of ovarian cancer with CD164 was assessed in a 97-patient tumor
tissue microarray. Overexpression or silence CD164 was to analyze the effect of CD164 on the proliferation, colony
formation and apoptosis via a mouse xenograft and western blotting analysis. The subcellular localization of CD164
was collected in the immunohistochemical and confocal analysis.
Results: Our data demonstrated that higher expression levels of CD164 were identified in malignant ovarian cancer
cell lines, such as SKOV3 and HeyA8. The clinicopathological correlation analysis showed that the upregulation of
CD164 protein was significantly associated with tumor grade and metastasis. The overexpression of CD164 in
human ovarian epithelial surface cells promoted cellular proliferation and colony formation and suppressed
apoptosis. These tumorigenicity effects of CD164 were reconfirmed in a mouse xenograft model. We also found
that the overexpression of CD164 proteins increased the amounts of CXCR4 and SDF-1α and activated the
SDF-1α/CXCR4 axis, inducing colony and sphere formation. Finally, we identified the subcellular localization of
CD164 in the nucleus and cytosol and found that nuclear CD164 might be involved in the regulation of the activity
of the CXCR4 promoter.
Conclusions: Our findings suggest that the increased expression of CD164 is involved in ovarian cancer
progression via the SDF-1α/CXCR4 axis, which promotes tumorigenicity. Thus, targeting CD164 may serve as a
potential ovarian cancer biomarker, and targeting CD164 may serve as a therapeutic modality in the management
of high-grade ovarian tumors.
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Ovarian carcinomas are among the most lethal gynecological
malignancies for women in the world [1,2]. Despite ad-
vances in treatment, including surgery and targeted
chemotherapy, the 5-year survival of patients with epithe-
lial ovarian cancer (EOC) remains only 45% [3]. The poor
ratio of survival to incidence in EOC patients results from* Correspondence: jchan9473@gmail.com
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reproduction in any medium, provided the orthe high percentage of cases diagnosed at an advanced
stage. Although some studies have shown that the fallo-
pian tube could be a source of ovarian cancer, most of the
ovarian cancers are classified as “epithelial” and are be-
lieved to arise from the surface of the ovary [4,5]. Ovarian
carcinomas are highly metastatic tumors that primarily in-
vade the surrounding tissues and serosal cavities, and their
spread through the systemic circulation is uncommon [6].
Although many previous studies have focused on the
mechanisms underlying the development and progression
of ovarian cancer [7-10], the actual series of events of
ovarian cancer tumorigenesis are not yet clear.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Quantification of the expression of CD164 in ovarian
cancer cell lines and an ovarian tissue array. a) Cell lysates from
indicated ovarian cells were subjected to immunoblot analysis with an
antibody against CD164 protein. α-tubulin was used as a loading
control. b) Immunohistochemical staining of malignant and normal
ovarian tissue section stained with rabbit anti-CD164 antibodies and
CD164 levels in representative ovarian tumor tissue. Scale bars = 50 μm.
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http://www.molecular-cancer.com/content/12/1/115CD164 (also known as endolyn) is a glycoprotein and a
type I integral transmembrane sialomucin. Studies have
shown that CD164 may serve as a signaling receptor
that regulates proliferation, adhesion and migration in
hematopoietic stem and progenitor cells [11,12]. CD164 is
also involved in the development and regeneration of skel-
etal muscle [13]. Furthermore, CD164 serves as a factor in
the regulation of prostate cancer cell adhesion to the hu-
man bone marrow endothelial monolayer [14]. Recently,
Li et al. reported that the mobility and metastasis of colon
cancer cells were decreased while CD164 expression was
knocked down, suggesting that CD164 may play an im-
portant role in colon cancer progression [15]. An earlier
study showed that CD164 acts as a component of a
CXCR4 complex and regulates the SDF-1α-mediated mi-
gration of CD133+ cells [11]. SDF-1α enhances the mRNA
expression of CD164 and alters the protein expression of
CD164 [14]. The CXCR4 chemokine receptor has been
implicated in many malignancies [14,15], and the SDF-
1α/CXCR4 axis has been shown to be involved in several
aspects of tumor progression, including angiogenesis,
metastasis and survival [16-20]. CD164 associates with
the chemokine receptor CXCR4 [13], possibly as a co-
receptor for the CXCR4 ligand SDF-1α. These results
reveal that CD164 may be the key molecule in the modu-
lation of the tumor progression.
In this study, the CD164 expression profiles of ovarian
cancer cells were measured and were suggested to have a
correlation with ovarian tumorigenesis processes, includ-
ing proliferation, migration and invasion. CD164 in hu-
man ovarian surface epithelial cells was overexpressed to
study the functional roles of CD164 and revealed that
CD164 might modulate the SDF-1α/CXCR4 axis to pro-
mote ovarian tumorigenesis via the induction of SDF-1α
and CXCR4. In summary, our work opens the door to
studying the functions of CD164 in tumorigenesis as well
as in stem cell differentiation.
Results
CD164 is highly expressed in ovarian cancer cell lines and
tissues and serves as a prognostic marker
To address whether CD164 is involved in ovarian tumori-
genesis, we measured the expression of CD164 in some
ovarian cancer cell lines and the normal ovarian cell line,
hOSE, by immunoblotting analysis. As shown in Figure 1a,
the highly invasive cell lines, HeyA8, SKOV3 and ES-2
cells, expressed higher levels of CD164 compared to
the less malignant cell lines, OVCAR3 and Caov3, and
the hOSE cells. To determine the association between the
abundance of the CD164 protein and ovarian cancer, we
used a tissue microarray containing normal ovarian tissue,
benign tumor tissue and different stages of malignant
tumors for immunohistochemical staining. The CD164
staining localized to both the cytoplasm and the cellmembrane, and most tumors were strongly stained in
their nuclei and had a uniform staining pattern in the
epithelial component but not in the stroma (Figure 1b).
Furthermore, tissues from different stages of ovarian can-
cers were stained to determine the amount of CD164 pro-
tein (+1 faint, +2 moderate, +3 strong and +4 very strong).
Our findings indicated that a high abundance of CD164
protein was only significantly correlated with high-
grade ovarian tumors (P < 0.001) (Table 1). Hence, the
expression level of the CD164 protein could be used as a
prognostic marker for ovarian cancer.
Overexpression of CD164 alters cell morphology and
induces malignant transformation/anchorage
independent growth in hOSE cells
To examine the transforming effect of CD164 in non-
cancer cells, such as hOSE, we overexpressed the CD164
gene (Figure 2a) and evaluated the effect of its overexpres-
sion on the cell morphology, proliferation, adhesion and
Table 1 Clinicopathological analysis of CD164 gene
expression in an ovarian cancer tissue array
Characteristics Total < = 3-fold >3-fold p-value
All cases 97 25 (25.8%) 72 (74.2%)
Age
<50 yrs 39 23 (58.9%) 16 (14.1%)
≥50 yrs 58 34 (58.6%) 24 (41.4%) 0.972
Stage
Early (T1 + T2) 72 51 (70.9%) 21 (29.1)
Late (T3) 25 5 (20.0%) 34 (87%) < 0.05
Grade
Low (1 & 2) 50 36 (72.0%) 14 (28.0%)
High (3) 46 5 (10.9%) 41 (89.1%) < 0.001
Histology
Serous 49 30 (61.2%) 19 (38.8%)
Others 48 34 (71.0%) 14 (29.0%) 0.317
Metastasis
Absent 73 46 (63.1%) 27 (36.9%)
Present 24 8 (33.4%) 16 (66.7%) < 0.05
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CD164 overexpression on cellular morphology was exam-
ined with phase-contrast microcopy, and the CD164-
overexpressing hOSE cells showed fewer cell-cell contacts
and exhibited scattering of cells (Figure 2b). Furthermore,
the CD164-overexpressing cells had lower adhesion ability
than the hOSE-vector control cells (Figure 2c). Addition-
ally, the cell proliferation rate was significantly increased
in the CD164-overexpressing hOSE cells in comparison to
the vector-control cells via the BrdU proliferation assay
(Figure 2d). In addition, the effect of CD164 on anchorage
independent growth was determined by the colony num-
bers and sizes after 4 weeks of growth in soft agar. The
hOSE-CD164 cells formed many more colonies than the
hOSE-vector control cells using an anchorage-independent
colony formation assay (Figure 2e). Interestingly, we also
observed a higher expression of the anti-apoptotic protein
Bcl-2 and a lower expression of the apoptotic protein Bax
in CD164-overexpressed hOSE cells (Figure 2f). These re-
sults suggested that CD164 modulates tumor progression
by increasing proliferation and anchorage-independent
growth through anti-apoptotic effects, and therefore, it
might play a role in the promotion of the tumorigenic po-
tential of ovarian surface epithelial cells.
CD164 overexpression promotes ovarian tumor formation
Based upon these observations, we hypothesized that
CD164 plays important roles in ovarian tumor growth
in vivo. Because generating tumors by subcutaneous in-
jection allows for easy monitoring of tumor growth, andintra-peritoneal injection allows tumor cells to grow in a
peritoneal microenvironment that mimics the microenvir-
onment of ovarian cancer tumors, we developed two
xenograft models in nude mice to evaluate the tumor
formation ability of the hOSE-CD164 and SKOV3 cells
(as a positive control). After 8 weeks of observation, the
volumes of the tumors formed by subcutaneous injection
of hOSE-CD164 cells was much greater than for SKOV3
cancer cells, and the injection of the hOSE-vector control
and parental cells resulted in no tumor formation
(Figure 3a and 3b). Furthermore, mice injected intraperi-
toneally with hOSE-CD164 cells but not hOSE-vector
control cells developed peritoneal tumors, and these peri-
toneal tumors were significantly larger than those in mice
injected with SKOV3 cells (Figure 3c). In addition, CD164
overexpression resulted in a greater formation of ascites in
the hOSE-CD164 injected mice than the SKOV3 injected
mice (Figure 3d).
The knock-down of CD164 expression led to reduced
tumorigenicity and enhanced the survival rate of cancer
cell xenografted mice
To investigate the functional roles of CD164 in tumori-
genicity, we used shRNA targeting CD164 gene expression
to investigate whether the downregulation of CD164 in
ovarian cells could inhibit tumor growth and increase the
survival time of xenografted mice. First, we established
two viral targeted CD164 shRNA constructs with a
doxycycline-inducible promoter, selected for successfully
transfected cells using puromycin, and induced the ex-
pression of the shRNA constructs with doxycycline for
48 hours. We analyzed the downregulation efficiency of
CD164 abundance in SKOV3 and HeyA8 cells by real-
time PCR and immunoblotting analysis (Additional file 1:
Figure S1 and Figure 4a and b). Next, we examined the ac-
tivation of apoptosis by measuring the cleavage abundance
of caspase-3 and PARP-1 proteins in the shCD164-
SKOV3 and shCD164-HeyA8 cells, and our data demon-
strated that the loss of CD164 induced cellular apoptosis
is these two cell lines (Figure 4b). We further examined
the antitumor effect of the downregulation of the CD164
protein in nude mice bearing shCD164-SKOV3 tumors.
Six weeks after the subcutaneous injection of shCD164-
SKOV3 and SKOV3-control cells, the mice were sacrificed,
and the tumor growth was assessed by tumor volume. The
volume of the tumors in the SKOV3-shCD164 groups was
significantly decreased compared with the SKOV3-control
cells (>90% reduction, n = 8, p < 0.001) (Figure 4c). On the
other hand, the Kaplan-Meier survival curves showed that
the SKOV3-shCD164 group had a significantly longer sur-
vival rate than the control group in the peritoneal injection
model (n = 8, p < 0.001) (Figure 4d). The first death oc-
curred at day 53 and 76, respectively, in the SKOV3-
control and shCD164 groups. These data demonstrated
Figure 2 CD164 overexpression alters cell morphology and induces malignant transformation/anchorage independent growth in
hOSE. a) Cell lysates from hOSE-CD164 cells were subjected to an immunoblot analysis with an antibody against the CD164 protein. α-tubulin
was used as a loading control. b) The morphology of hOSE-CD164 cells compared with hOSE parental and hOSE-vector control cells by phase-contrast
microscopy. (×100 magnification and Scale bars = 50 μm). c) The adhesive ability of hOSE-CD164 and control cells was detected by an adhesion assay.
**p < 0.01 (three independent experiments were performed and the data are expressed as the means ± s.e.m.). d) Proliferation of hOSE-CD164 cells
and control cells were analyzed using a BrdU proliferative assay (three independent experiments and data were mean ± s.e.m.). e) Effect of CD164
overexpression on the colony formation ability of hOSE cells. Soft agar colony formation of hOSE-CD164 and BEAS2B-CD164 cells paired with control
cells was calculated after 28 days of culture. The graph showed the number of colonies (means ± s.e.m.) after 4 weeks of culture for three independent
experiments. The p values (determined by Student’s t test) were relative to control cells. **p < 0.01 (three independent experiments and data were
means ± s.e.m.). f) Cell lysates from hOSE-CD164 cells were subjected to immunoblot analysis for antibodies against anti-apoptotic Bcl-2 and apoptotic
Bax protein. α-tubulin was used as a loading control.
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ovarian cancer cells induced cellular apoptosis and reduced
tumor growth to increase the survival time of xenografted
mice.
CD164 overexpression upregulates the SDF-1α/CXCR4
complex and activates downstream PI3K/Akt signaling
The PI3 kinase/Akt pathway is commonly dysregulated
in human cancers and functions in such processes as
proliferation, survival and motility [21-23]. CXCR4, the
upstream molecule of the PI3 kinase/Akt pathway, has
been shown to directly or indirectly regulate tumor
growth [20]. Furthermore, recent reports have indicatedthat CD164 interacts with CXCR4 and might regulate
the pathway downstream of CXCR4 [11]. Our co-
immunoprecipitation analysis showed that CD164 did
complex with CXCR4 and CXCR7 (Figure 5a). We fur-
ther addressed whether the SDF1α/CXCR4 axis is in-
volved in CD164-induced ovarian tumor growth. The
protein level of CXCR4 was induced, and its down-
stream signaling molecules, pPDK1 and pAktSer473, were
activated in CD164 overexpressing hOSE cells compared
with control cells (Figure 5b). Furthermore, our data
showed that CD164 induced CXCR7 expression, another
SDF-1α receptor, and reduced p53 and its target p21 ex-
pression (Figure 5b). We also confirmed that CD164 had
Figure 3 CD164 overexpression promotes tumor formation in nude mice. a) The tumor growth of hOSE-CD164 cells, control cells and
SKOV3 cells subcutaneously injected into female athymic nude mice (n = 8, each group) was assessed every 5 days for 45 days by measuring two
perpendicular diameters and calculating the tumor volume in mm3. Tumor size was measured during 7–8 weeks and calculated as follows:
volume = length ×width2 × 1/2. ** p < 0.01. Data represent the means ± SEM. b) Macroscopic appearance of hOSE-CD164 (top and bottom, red), hOSE
control (top, yellow) and SKOV3 (bottom, yellow) tumors formed subcutaneous tumors. c) Quantification of the tumor weight of hOSE-vector and
hOSE-CD164 cells (4 × 106) after subcutaneous injection in the flanks of nude mice (n = 8, each group). Tumor weight was measured in the hOSE-CD164
cells and compared with hOSE-vector cells (*** p < 0.001) and SKOV3 (** p < 0.01) nude mice. d) Macroscopic appearance of hOSE-CD164 tumors
(upper) spread and disseminated in the peritoneal cavity (bottom, arrows). e) hOSE-CD164 cells, control cells and SKOV3 cells (4 × 106) were injected
into the peritoneal cavity of nude mice. Tumor weight was measured in the hOSE-CD164 cells and compared with hOSE-vector cells (*** p < 0.001)
or SKOV3 (** p < 0.01) nude mice. f) At autopsy, tumors were excised and ascite fluid was collected and measured. *** p < 0.001.
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levels in some ovarian cancer cells (Figure 5c). Several
studies have reported that SDF1α stimulation leads to
the activation of CXCR4 by phosphorylation of the cyto-
plasmic domain of CXCR4 for the activation of its
downstream signaling pathways, MAPK, PI3K and STAT
[24,25]. Hence, we investigated whether CD164 also in-
duced SDF-1α production, and our ELISA data revealed
more SDF-1α production in hOSE-CD164 cells and the
cells isolated from the peritoneal xenografted tumor cells
than in the other cancer cell lines (Figure 5d). Next, we
designed a shRNA construct to silence the endogenous
CXCR4 expression in hOSE-CD164 cells and found a de-
crease in the levels of pPDK1 and pAktSer-473 (Figure 5e).
Finally, we observed a selective CXCR4 antagonist,
AMD3100, and the silencing of CXCR4 expression in
hOSE-CD164 cells counteracted the inductive effect of
CD164 overexpression on colony number and anchorage
independent growth (Figure 5f). Taken together, our data
indicated that CD164 induced the expression of SDF-1αand CXCR4 to activate the SDF-1α/CXCR4 signaling
pathway, causing tumorigenesis.
Nuclear CD164 enhanced the promoter activity of the
CXCR4 gene
Based on our tissue array data, which showed that
CD164 proteins are located in the nucleus, we attempted
to address whether the CD164 protein can directly acti-
vate the SDF-1α/CXCR4 axis via its function in the nu-
cleus. We transiently transfected the CD164-EGFP
vector into hOSE cells and observed, via a confocal
microscope, that a proportion of the CD164 proteins
were localized to the nucleus (Figure 6a). We further
fractionated the lysates into cytoplasmic and nuclear
fractions and reconfirmed that a proportion of the
CD164 proteins were localized in the nucleus (Figure 6b).
We examined the possibility that nuclear CD164 modu-
lates the SDF-1α/CXCR4 axis via the enhancement of
the CXCR4 promoter activity using the dual-luciferase
reporter assay. The results revealed that CD164
Figure 4 CD164 downregulation rescues the effects of CD164 overexpression on tumorigenicity in nude mice. a) Total RNAs were
extracted from SKOV3-shCD164, HeyA8-shCD164 and respective control cells for the qRT-PCR analysis. Quantitative analysis of CD164 transcript
levels relative to GAPDH was calculated and compared with SKOV3 or HeyA8 control cells. b) Doxycycline-inducible SKOV3-shCD164 and
HeyA8-shCD164 cells were treated with 5 μg/ml doxycycline. After 48 hours, the cells were harvested and subjected to immunoblot analysis with
antibody against CD164 protein, cleaved PARP and caspase 3 and its cleaved fragment. α-tubulin was used as a loading control. c and d) SKOV3-
shCD164 cells and SKOV3-control cells were subcutaneously injected in the flanks of nude mice (n = 8). Nude mice were treated continuously with
Dox and harvested at 8 weeks after Dox treatment. Tumor sizes and tumor weight c) were measured and analyzed, and Kaplan-Meier survival curves
were recorded d).
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dependent manner in hOSE cells (Figure 6c).
CD164 induces stem cell-specific transcription factors and
form spheres
Cancer stem cells (CSCs) have been proposed to initiate
and maintain tumor growth, and CD133 is a well-
defined cancer stem cell marker [26,27]. A recent report
indicated that the OSE expresses CD133 and other CSC
markers, and malignant transformation can be induced
in the OSE [28]. CXCR4 is highly expressed in various
types of adult stem cells and CD133+ high CSCs [29].
The SDF-1α/CXCR4 axis plays an important role in
tumor progression and metastasis and indicates poor
prognosis in ovarian cancer patients [30]. CD164 has
been proven to be highly expressed in hematopoietic
stem cells and other stem cells [11,31] and to be in-
volved in some instances of cancer cell metastasis to
other sites [14,15]. Our results demonstrated that
CD164 also has important roles in the regulation of
some stem cell specific transcriptional factors, such as
Nanog, Oct4 and Sox-2 (Figure 7a). To investigate
whether CD164 was involved in regulating the charac-
teristics of CSCs, we determined the self-renewalcapability of CD164-hOSE by an ultralow plate system.
The sphere formation results showed that CD164 had
sphere formation potential and knockdown of CXCR4 in
CD164-hOSE significantly suppressed its ability to form
spheres (Figure 7b). Furthermore, we double checked
some important CSC markers, such as Nanog, Oct4 and
Sox-2, whether induced by overexpression of CD164 in
hOSE cells (Figure 7c). The induction of Nanog, Oct4
and Sox-2 proteins was consistent with their genes by
CD164 (Figure 7a and c). Our findings suggest that
CD164 may be involved in the self-renewal of CSCs
through well-known markers and CXCR4. Therefore,
CD164 overexpression might induce the OSE cells to be-
come CSCs by activating the SDF-1α/CXCR4 axis, and
CD164 could be a new marker for CSCs.
Discussion
Previous studies have demonstrated the inhibition of cell
proliferation by CD164 knock-down in colon cancer cells
[15]. In this study, we explored the functional roles of
CD164 in tumorigenesis using genetic loss-of-function
and gain-of-function approaches. Overexpressing CD164
in hOSE cells may have the ability to induce tumor cell
growth, proliferation, migration and self-renewal mediated
Figure 5 CD164 overexpression upregulates the SDF1α /CXCR4 axis to activate downstream PI3K/Akt signaling pathway. a-b) Cell
lysates from hOSE-CD164 and hOSE-vector cells were subjected to a) immunoprecipitation with antibody against CXCR4 and immunoblot
analysis with antibody against CD164 and a control antibody (upper) or immunoprecipitation with antibody against CD164 and immunoblot
analysis with antibodies against CXCR4 and CXCR7 and a control antibody (bottom); b) immunoblot analysis with antibodies against CD164,
CXCR4, pPDK1, pAkt and its phosphorylated form pAktSer-473, CXCR7, p53 and p21. α-tubulin was used as a loading control. c) Quantitative mRNA
analysis of CD164, CXCR4 and CXCR7 in hOSE-CD164 cells and indicated ovarian cells was performed by qRT-PCR, and mRNA levels were normalized
with individual GAPDH mRNA. Fold changes of specific mRNA expression were compared with that of hOSE control cells. d) The amount of SDF1α
in culture medium from hOSE-CD164 cells and indicated ovarian cells was measured using an ELISA analysis. e) The hOSE-CD164 cells showed
downregulated CXCR4 expression and were subjected to immunoblot analysis with antibodies against CXCR4, pPDK1 and pAktSer-473. α-tubulin was
used as a loading control. f) For the colony formation analysis, the hOSE-CD164 cells were treated with the CXCR4 antagonist AMD3100 or CXCR4 was
downregulated using shRNA. Quantitation of anchorage-independent growth of indicated conditioned cells was performed using anchorage
independent assay. The presented data are the means of three experiments (means ± S.D.; n = 3).
Huang et al. Molecular Cancer 2013, 12:115 Page 7 of 13
http://www.molecular-cancer.com/content/12/1/115through the induction of SDF-1α and CXCR4, which acti-
vates the SDF-1α/CXCR4 signaling pathway. An import-
ant result from the present study was that the nuclear
localization of CD164 induced CXCR4 gene expression
through the enhancement of CXCR4 promoter activity,
suggesting that CD164 might be a potential transcription
factor. The detailed mechanism of CD164 for this regula-
tory role needs to be further investigated. However, the ef-
fects of altering the abundance of CD164 on the
modulation of cell survival and proliferation mediatedthrough the SDF-1α/CXCR4 (or SDF-1α/CXCR4/CXCR7)
axis and some stem cell specific transcriptional factors,
such as Nanog, Oct4 and Sox-2, in ovarian epithelial cells
was supported by similar mechanisms in the metastasis of
CSCs and the trafficking of normal stem cells and pro-
vided promising results. In addition to above mentioned
regulated genes by CD164, our mRNA microarray data
also demonstrated that at least thousands of target genes
were positively or negatively regulated in the hOSE-
CD164 cells (data not shown). Hence, the tumorigenic
Figure 6 Nuclear CD164 upregulates CXCR4 promoter activity.
a) Representative hOSE cells transiently transfected with EGFP–tagged
CD164 constructs are shown. Approximately 100 transfected cells were
examined to evaluate the intracellular distribution of each of the EGFP
fusion proteins under a confocal microscope. Nuclei were stained with
TOTO-3. Bar = 20 μm. b) Fractionated cytosolic and nuclear lysates from
hOSE-CD164 and hOSE-vector cells were subjected to immunoblot
analysis with antibody against CD164. α-tubulin was used as a loading
control. c) Indicated amount of CXCR4 reporter DNAs were transiently
transfected into hOSE-CD164 and hOSE-vector cells. After 36 hours, the
luciferase activity in the transfected cell extracts was determined and
the fold induction of the activity was estimated relative to that of cells
transfected with the control vector in hOSE-vector cells. The presented
data are the means of three experiments (means ± S.D.; n = 3).
Huang et al. Molecular Cancer 2013, 12:115 Page 8 of 13
http://www.molecular-cancer.com/content/12/1/115capacity of CD164 might be mediated through its newly de-
fined transcription factor function in multiple targets, in-
cluding p53-dependent pathway, consistently that ovariancarcinogenesis is identified by multiple genetic alterations,
combined transduction of mutant p53-KrasV12-AKT-c-myc,
using hOSE tumorigenesis model [32].
The SDF-1α/CXCR4 axis plays critical roles in many
physiological processes that involve cell migration and cell
fate decisions, ranging from stem cell homing, angiogen-
esis and neuronal development to immune cell trafficking
[20,33-36]. The predominant SDF-1α receptor is believed
to be CXCR4, and signaling through CXCR4 alters the
ability of cancer cell lines to adhere to the endothelium
and invade through the extracellular matrix components,
such as MMP-9, in the bone marrow [37,38]. Another
highly important function of the SDF-1α/CXCR4 axis is
related to tissue repair and regeneration [39]. CD164 asso-
ciates with the chemokine receptor CXCR4, possibly as a
co-receptor for SDF-1α, which is a likely mechanism by
which CD164 influences migration and myotube forma-
tion and modulates the SDF-1α-mediated migration of
umbilical cord blood CD133+ cells [11]. In addition,
CD164 is most likely involved in the regulation of cell ad-
hesion and proliferation via specific intercellular recogni-
tion [14]. In addition to CXCR4 as a receptor for SDF-1α,
CXCR7 is another receptor and it can work alone or
heterodimerize with CXCR4 to modulate, positively or
negatively, CXCR4 signaling from SDF-1α [40,41]. The
functional roles of CXCR7 are identified as CXCR4 does
in many cancers, including prostate cancers [42,43].
Hence, our proposed the SDF-1α/CXCR4 axis by CD164
might be modified as the SDF-1α/CXCR4/CXCR7 axis
because specific CXCR4 inhibitor or shCXCR4 not fully
suppressed CD164-induced colony formation and sphere
formation (Figure 5f and 7d). We had no further evidence
of the CXCR7 gene regulation as CD164-directed CXCR4
promoter activity (Figure 6c). Hence, CXCR7 induction
might be mediated through the direct effect from SDF-1α
or the transactivation activity of CD164 in our case. It
remains to be investigated in the future.
HIF-1α can bind to the CD164 promoter and induced
CD164 gene expression; hence, hypoxia induction also
leads to the upregulation of the CD164 gene expression
via the transcription factor function of HIF-1α [44]. In
addition to the induction of CD164 gene expression, HIF-
1α enhances the expression and function of CXCR4,
CXCR7 and SDF-1α on the surface of normal and malig-
nant cells [43,45]. SDF-1α also enhances the expression of
CD164 mRNA and alters the expression of the CD164
protein in prostate cancer cell lines [14]. In prostate car-
cinomas, not only the HIF-1α/AP-1 complex but also
intracellular Zn2+ are involved in the induction of CD164
gene expression [44,46]. Combined with the results of the
present study, we propose one positive-feedback working
model in which environmental cues, such as hypoxia in
tumorigenesis, induce CD164 overexpression and increase
the components of the SDF-1α/CXCR4 axis to activate its
Figure 7 The effects of CD164 on stem cell marker and sphere formation. a) A quantitative mRNA analysis of ALDH-1, CD44, Nanog, Nestin,
Oct4 and Sox2 in hOSE and hOSE-CD164 cells was performed by qRT-PCR, and mRNA levels are expressed relative to individual GAPDH mRNA.
The presented data are the means of three experiments (means ± S.D.; n = 3). b) Spheroid formation of hOSE and hOSE-CD164 and shCXCR4 cells
after culture in ultralow plates for 7 days. **p < 0.01. c) Western blot analysis of hOSE and hOSE.CD164 cell lysates were subject to against
antibodies for CSC markers, including Nanog, Oct4 and Sox-2. α-tubulin was used as a loading control.
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tion, invasion and self-renewal in ovary cancer cells. A
recent study suggests that incorporating an inhibitor of
CXCR4 into drug protocols for ovarian cancer may improve
outcomes for patients with this disease [47]. Consequently,
strategies aimed at modulating the SDF-1α/CXCR4 axis via
the regulation of CD164 abundance could have important
clinical applications in both tissue engineering and in
clinical hematology and oncology for the inhibition of
the proliferation and metastasis of CSCs.
Materials and methods
Cell lines and reagents
The human ovarian surface epithelial (hOSE) cell
line OSE10, a gift from Professor Hidetaka Katabuchi
(Kumamoto University, Japan) [48], was maintained in
MCDB105 medium (Sigma Chemical Co., St. Louis,
MO, USA) supplemented with 10% FBS, 10 ng/ml EGF
(Sigma) and 400 ng/ml hydrocortisone (Sigma). The
HEYA8, OVCAR3, ES-2 and SKOV3 human ovarian
cancer cell lines were from the American type Culture
Collection (Rockville, MD, USA) and were cultured with
10% fetal calf serum, 2 mM L-glutamine, 100 U/mL
penicillin and 100 mg/mL streptomycin at 37°C in a hu-
midified atmosphere consisting of 5% CO2. The CD164
polyclonal antibody (clone 502021) was purchased from
R&D systems (Oxford, UK). CXCR4 antibody (clone
ab2074) was obtained from Abcam (Cambridge, United
Kingdom). CXCR7 antibody (clone C1C2), Nanog anti-
body (GTX627421) and Sox2 antibody (GTX62242)were purchased from Genetex (Taipei, Taiwan, ROC).
Akt antibody, the phospho-Akt antibody, histone H3
antibody and Oct4 antibody were purchased from Cell
Signaling Technology (Danvers, MA, USA). p53 (DO-1)
and p21 (C-19) antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
Lentiviral infections
The lentiviral CD164 shRNA constructs were purchased
from the National RNAi Core Facility in Academic Sinica,
Taipei, Taiwan. The target sequences of these shRNAs are
described in Table 2. Lentiviruses were produced by
cotransfecting the shRNA-expression vectors pMD2.G
and psPAX2 into 293 T cells using calcium phosphate.
Viral supernatants were harvested and used to infect
SKOV3 and HeyA8 cells with 8 μg/mL polybrene. Cells
were selected using 2 μg/mL puromycin. CD164
overexpressing cells were established by infection with the
lentivirus-expressing pWPXL-vector with the human
CD164 coding sequence.
Isolation of total RNA and analysis of quantitative real-
time PCR
Total mRNA was extracted using the TRIzol reagent
(Invitrogen, Carlsbad, CA, USA), and reverse transcription
was performed using an RT–PCR kit (Invitrogen). Ana-
lysis of quantitative real-time PCR (qPCR) was performed
on an ABI 7500 instrument (Applied Biosystems, Foster
City, CA, USA) using the SYBR Green PCR Master Mix
(Applied Biosystems). Each measurement was performed
Table 2 shRNA sequence list
shRNA name Sequence (5′ to3′)
CD164 shRNA 1 GCTATTGTTCACATAACTCAA
CD164 shRNA 2 CGTGACGACTTTAGCGCCCAT
CXCR4 shRNA1 AGATAACTACACCGAGGAAAT
CXCR4 shRNA2 TCCTGTCCTGCTATTGCATTA
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was conducted, and GAPDH was applied as the internal
housekeeping gene control. All PCR primers were listed in
Table 3.Immunoblot assay
The cell lysates were prepared in RIPA lysis buffer
(150 mM NaCl, 1% NP40, 0.5% DOC, 50 mM Tris–HCl
at pH 8, 0.1% SDS, 10% glycerol, 5 mM EDTA, 20 mM
NaF and 1 mM Na3VO4) supplemented with 1 mg/ml
each of pepstatin, leupeptin, and aprotinin and 200 mg/ml
phenyl-methylsulfonyl-fluoride. The lysates were sepa-
rated by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis, transferred onto polyvinylidine difluoride
membranes (Millipore, USA) and detected by using the
primary antibodies indicated above.Table 3 Primer sequence list




















GAPDH-R TCTCTTCCTCTTGTGCTCTTGPatients and tissue microarray
Surgical resection of 97 tumor samples from primary
ovarian cancer patients and normal ovary samples from
a commercial ovarian cancer tissue array (OVC1021,
Pantomics, Inc.) were studied.
Immunohistochemistry
The tumor tissues were dissected from intraperitoneally
injected animals. The tissues were processed by fixation
in 4% buffered formalin and then embedment in paraf-
fin wax. The sections (5 μm) were stained with the
hematoxylin and eosin stained for histopathologic ana-
lysis. After the sections were dried overnight at 37°C,
they were deparaffinized with xylene. The sections were
treated with an antigen retrieval solution (Target Re-
trieval, Dakocytomation, Carpinteria, CA, USA) at 95°C
for 15 minutes and incubated overnight at 4°C with a
rabbit monoclonal antihuman CXCR4 antibody (Abcam)
and polyclonal sheep antihuman CD164 antibody
(R&D), both at a dilution of 1:1000. The next day, the
sections were incubated with streptavidin linked to horse-
radish peroxidase (Dako Corp., Carpinteria, CA, USA)
and then with a secondary mouse anti-immunoglobulin
antibody linked to biotin; they were then developed with
diamino-benzamidine (DAB) and counterstained with
hematoxylin.
Animals
All of the animal experiments were approved (IACUC
NO.12-094) and conducted under the guidance of the
Institutional Animal Care and Use Committee (accredited
by the Association for Assessment and Accreditation of
Laboratory Animal Care International), National Defense
Medical Center, Taipei, Taiwan. A total of 4x106 cells in
0.1 mL of PBS were injected subcutaneously or intraperi-
toneally (n = 8 for each group) into female athymic nude
mice of 7–8 weeks of age, and tumor growth was followed
for 7–8 weeks. After sacrifice, the solid tumors and ascites
were quantified and assayed. For the survival study, nude
mice were intraperitoneally injected with 4x106 cells and
the time of death of each animal was recorded (n = 8 for
each group).
Cell proliferation assay
hOSE cells were seeded at a density of 1x104 cells/ml
(100 μl/well) into 96-well microplates with complete
medium and were cultured for 24 hr. After 24 hr of in-
cubation, the cell proliferation was assessed by the BrdU
assay method. The absorbance at 450 nm was deter-
mined using a microplate reader.
Soft agar colony formation assay
Bottom agar (0.7%) was plated onto six-well plates and
10,000 cells were plated in triplicate, incubated at 37°C
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onies were allowed to form over 2–3 weeks and were then
stained by crystal violet for counting. Images were taken
at 10× magnification.
ELISA
Quantitative ELISA (Quantikine, R&D Systems) was
used to determine the level of SDF-1α in the culture
medium. The samples and standards were pipetted into
wells pre-coated with a monoclonal antibody specific for
SDF-1α. After washing, an enzyme-linked polyclonal
antibody specific for SDF-1α was added. The optical
density was measured using a microplate reader set to
450 nm with a correction at 540 nm.
Coimmunoprecipitation
Cells were lysed for 30 min at 4°C in immunoprecipitation
(IP) buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% NP-40,
0.75 mM MTA, 0.2 mM Na3VO3, and 0.2 mM PMSF).
Lysates were incubated with CD164 and CXCR4 antibody
overnight at 4°C, then pre-treated protein-G Magnetic
Beads (Millipore) incubated 2 hours at 4°C. Beads were
wash and resuspended in sample buffer and samples
subjected to SDS-PAGE/Western blotting. Blots were
revealed with sheep anti-CD164 (1:1000), rabbit anti-
CXCR4 (1:1000), CXCR7 (1:500), HRP-conjugated anti-
sheep (1:1000) or anti-rabbit (1:1000) antibodies were used
as secondary antibodies. Chemiluminescence was detected
by ECL (Pierce, Rockford, IL, USA).
Immunofluorescence
The cells were grown on coverslips, fixed with a 4%
paraformaldehyde-PBS solution and permeabilized with
0.2% Triton X-100 in PBS. Following fixation, the cells
were blocked with 5% bovine serum albumin (BSA) for
1 hour and incubated at 4°C for 18 hours with a primary
antibody (1:100) in 5% BSA in PBS. The cells were then
incubated with a secondary antibody (1:200) at room
temperature for 45 minutes in stock buffer. The photo-
graphs were taken with the ×63/oil 1.4 DIC objective of
a Zeiss LSM510 META confocal laser-scanning micro-
scope (Axiophot 2, ZEISS) (Carl Zeiss, Jena, Germany).
Luciferase reporter assay
To determine the chemokine promoter activity, hOSE
cells were cultured to 80% confluency in six-well plates
and transfected in each well (24-well plate) with jetPEI
(Polyplus-transfection, France), according to the manu-
facturer’s protocol. The total DNA for transfection was
adjusted to 1.0 μg by the addition of the empty vector.
The luciferase assays were performed with the Promega
Luciferase Assay Kit (Madison, WI, USA), and the mea-
surements were expressed numerically as relative lightunits (RLU). Luciferase activities are given as the means
and standard deviations of two transfected sets of cells.
The results shown are representative of at least three
independent experiments.
Sphere formation assay
Tumor spheres were generated in serum-free sphere
medium consisting of Dulbecco’s modified Eagle’s
medium and supplemented with 20 ng/mL epidermal
growth factor (EGF; Sigma) and 20 ng/mL basic fibroblast
growth factor (bFGF; Sigma). hOSE and hOSE.CD164
cells were seeding 1000 cells (10 cells per well) in 96-well
ultra-low attachment plates in 100 μL of serum free
medium and cultured for up to 7 days. The number of
spheres was evaluated after 4 days.
Statistical analysis
Data from different experiments were presented as the
means ± SEM and were analyzed by the two-tailed Stu-
dent’s t test. P < 0.01 was considered significant. The data
were the means ± standard deviations (SD) for at least
three independent experiments. Statistical significance
was assessed using a one-way ANOVA and Student’s
t-test. * indicates P < 0.05, **P < 0.01 and *** P < 0.001,
respectively, when compared with the control.
Additional file
Additional file 1: Figure S1. Inducible downregulation of CD164 in
Hey8 and Skov3 cells. SKOV3-shCD164 and HeyA8-shCD164 cells were
treated with 0, 1, 2 and 5 μg/ml of Dox for 48 hours, and then, CD164
protein expression was analyzed by immunoblot with an antibody
against the CD164 protein. α-tubulin was used as a loading control.
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